Ann: Updated guidance for PAT-DX1 phase 1 clinical study, page-102

"what you expect to discover from learning the CDMO they used."
I am just sticky-beaking and filling in time for something to do while we await the next announcement.
"If CEOs were to step down every time a biotech ran into an issue along their development, there'd be a new boss every month."
I agree with that statement. Dr. Campbell was appointed as a non-executive director in November 2014 and was appointed CEO in April 2015. I thought I would see just what has been achieved in that time and perhaps post a chronological list of events. I am only through to the end of 2018 and the list is already too long for me to put in a post. I would venture to suggest that we would not have PAT-DX1 and PAT-DX3 were it not for Dr. Campbell. Nor would we have a world-wide licence for 3E10 (deoxymab) nor the patents that the company now holds. And all of that in addition to the pre-clinical test results that have been achieved.
As a long term holder I am still very positive PAB and happy with the performance of the CEO.